Latest News and Press Releases

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The atopic dermatitis market...

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with AD

The first child has been enrolled in Phase 2 INTEGUMENT-INFANT study evaluating the safety and tolerability of investigational ZORYVE cream for AD

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more...

Arcutis to present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, taking place in Nashville, TN, from June 6-7, 2025.

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Prurigo Nodularis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...

New York, USA, May 20, 2025 (GLOBE NEWSWIRE) -- Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The moderate to severe atopic dermatitis...

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The report delivers a...

Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial Authorisation First indication will be psoriatic arthritis, a...

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June...